143 related articles for article (PubMed ID: 31464063)
1. Short-term fully closed-loop insulin delivery using faster insulin aspart compared with standard insulin aspart in type 2 diabetes.
Bally L; Herzig D; Ruan Y; Wilinska ME; Semmo M; Vogt A; Wertli MM; Vogt B; Stettler C; Hovorka R
Diabetes Obes Metab; 2019 Dec; 21(12):2718-2722. PubMed ID: 31464063
[TBL] [Abstract][Full Text] [Related]
2. Faster Compared With Standard Insulin Aspart During Day-and-Night Fully Closed-Loop Insulin Therapy in Type 1 Diabetes: A Double-Blind Randomized Crossover Trial.
Dovc K; Piona C; Yeşiltepe Mutlu G; Bratina N; Jenko Bizjan B; Lepej D; Nimri R; Atlas E; Muller I; Kordonouri O; Biester T; Danne T; Phillip M; Battelino T
Diabetes Care; 2020 Jan; 43(1):29-36. PubMed ID: 31575640
[TBL] [Abstract][Full Text] [Related]
3. Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study.
Boughton CK; Hartnell S; Thabit H; Poettler T; Herzig D; Wilinska ME; Ashcroft NL; Sibayan J; Cohen N; Calhoun P; Bally L; Mader JK; Evans M; Leelarathna L; Hovorka R
Diabetes Obes Metab; 2021 Jun; 23(6):1389-1396. PubMed ID: 33606901
[TBL] [Abstract][Full Text] [Related]
4. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.
Haidar A; Legault L; Dallaire M; Alkhateeb A; Coriati A; Messier V; Cheng P; Millette M; Boulet B; Rabasa-Lhoret R
CMAJ; 2013 Mar; 185(4):297-305. PubMed ID: 23359039
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.
Mathieu C; Bode BW; Franek E; Philis-Tsimikas A; Rose L; Graungaard T; Birk Østerskov A; Russell-Jones D
Diabetes Obes Metab; 2018 May; 20(5):1148-1155. PubMed ID: 29316130
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of Faster and Standard Insulin Aspart During Fully Closed-Loop Insulin Delivery in Type 2 Diabetes.
Herzig D; Dehais J; Prost JC; Nakas CT; Stettler C; Bally L; Hovorka R
Diabetes Technol Ther; 2020 Sep; 22(9):691-696. PubMed ID: 31999478
[No Abstract] [Full Text] [Related]
7. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
[TBL] [Abstract][Full Text] [Related]
8. Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes.
Zijlstra E; Demissie M; Graungaard T; Heise T; Nosek L; Bode B
J Diabetes Sci Technol; 2018 Jan; 12(1):145-151. PubMed ID: 28918652
[TBL] [Abstract][Full Text] [Related]
9. Effect of fully automated closed-loop insulin delivery using faster aspart versus standard aspart on gluco-regulatory hormones in type 2 diabetes.
Herzig D; Studer D; Nakas CT; Kuenzli C; Stauffer TP; Hovorka R; Bally L
Diabetes Obes Metab; 2021 Jan; 23(1):228-233. PubMed ID: 32902125
[TBL] [Abstract][Full Text] [Related]
10. A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial.
Tsoukas MA; Majdpour D; Yale JF; Fathi AE; Garfield N; Rutkowski J; Rene J; Legault L; Haidar A
Lancet Digit Health; 2021 Nov; 3(11):e723-e732. PubMed ID: 34580055
[TBL] [Abstract][Full Text] [Related]
11. Safety, efficacy and glucose turnover of reduced prandial boluses during closed-loop therapy in adolescents with type 1 diabetes: a randomized clinical trial.
Elleri D; Biagioni M; Allen JM; Kumareswaran K; Leelarathna L; Caldwell K; Nodale M; Wilinska ME; Haidar A; Calhoun P; Kollman C; Jackson NC; Umpleby AM; Acerini CL; Dunger DB; Hovorka R
Diabetes Obes Metab; 2015 Dec; 17(12):1173-9. PubMed ID: 26257323
[TBL] [Abstract][Full Text] [Related]
12. [The comparison of insulin aspart and human soluble insulin used in insulin pump therapy in newly diagnosed type 2 diabetic patients].
Li YB; Liu J; Liao ZH; Liao Y; Deng WP; Weng JP
Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(35):2472-6. PubMed ID: 16321271
[TBL] [Abstract][Full Text] [Related]
13. Fast-acting insulin aspart in people with type 2 diabetes: Earlier onset and greater initial exposure and glucose-lowering effect compared with insulin aspart.
Pieber TR; Svehlikova E; Brunner M; Halberg IB; Due Thomsen KM; Haahr H
Diabetes Obes Metab; 2019 Sep; 21(9):2068-2075. PubMed ID: 31069935
[TBL] [Abstract][Full Text] [Related]
14. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes.
Ranjan A; Schmidt S; Madsbad S; Holst JJ; Nørgaard K
Diabetes Obes Metab; 2016 Apr; 18(4):410-8. PubMed ID: 26743775
[TBL] [Abstract][Full Text] [Related]
15. A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus.
Heise T; Hövelmann U; Zijlstra E; Stender-Petersen K; Jacobsen JB; Haahr H
Drugs Aging; 2017 Jan; 34(1):29-38. PubMed ID: 27873152
[TBL] [Abstract][Full Text] [Related]
16. Hybrid Closed-Loop with Faster Insulin Aspart Compared with Standard Insulin Aspart in Very Young Children with Type 1 Diabetes: A Double-Blind, Multicenter, Randomized, Crossover Study.
Ware J; Allen JM; Boughton CK; Cezar A; Hartnell S; Wilinska ME; Thankamony A; Deakin M; Leyland H; Phelan K; Thornborough K; Hovorka R
Diabetes Technol Ther; 2023 Jun; 25(6):431-436. PubMed ID: 36880866
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial.
Heise T; Zijlstra E; Nosek L; Rikte T; Haahr H
Diabetes Obes Metab; 2017 Feb; 19(2):208-215. PubMed ID: 27709762
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial.
Ruan Y; Elleri D; Allen JM; Tauschmann M; Wilinska ME; Dunger DB; Hovorka R
Diabetologia; 2015 Apr; 58(4):687-90. PubMed ID: 25537835
[TBL] [Abstract][Full Text] [Related]
19. A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5).
Klonoff DC; Evans ML; Lane W; Kempe HP; Renard E; DeVries JH; Graungaard T; Hyseni A; Gondolf T; Battelino T
Diabetes Obes Metab; 2019 Apr; 21(4):961-967. PubMed ID: 30537180
[TBL] [Abstract][Full Text] [Related]
20. Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial.
Rodbard HW; Visco VE; Andersen H; Hiort LC; Shu DH
Lancet Diabetes Endocrinol; 2014 Jan; 2(1):30-7. PubMed ID: 24622667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
